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ABSTRACT | Purpose: To evaluate the possible protective 
effect of breast milk against retinopathy of prematurity by 
comparing the amount of breast milk received by patients 
who developed retinopathy of prematurity and those who did 
not and to determine both the required minimum amount of 
breast milk and the time of life during which neonates need to 
receive breast milk for this effect to be significant. Methods: 
Cohort study of newborns with a birth weight of <1500 g or 
gestational age of <32 weeks, or both, born between January 
2011 and October 2014 and hospitalized within the first 24 h 
of life in the Hospital Criança Conceição Neonatal Intensive 
Care Unit in Porto Alegre, RS, Brazil. Results: The prevalence 
of retinopathy of prematurity of any degree was 31% (100 of 
323 patients) and that of severe retinopathy of prematurity 
was of 9% (29 of 323 patients). The median amounts of breast 
milk received daily by patients with and without retinopathy 
of prematurity were 4.9 mL/kg (interquartile range, 0.3-15.4) 
and 10.2 mL/kg (1.5-25.5), respectively. The amount of breast 
milk received in the first 6 weeks of life was inversely associated 
with the incidence of both retinopathy of prematurity of any 
degree and severe retinopathy of prematurity in the univariate 
analyses. However, the statistical significance was maintained 
only during the sixth week of life in a per-period multivariate 
analysis controlling for confounding factors. Conclusions: Small 
amounts of breast milk are inadequate to prevent retinopathy 
of prematurity in premature newborns at risk for the disease.
Keywords: Retinopathy of prematurity; Milk, human; Breast 
feeding; Infant, very low birth weight; Insulin-like growth factor I; 
Infant, premature
RESUMO | Objetivos: Avaliar o possível efeito protetor do 
leite materno contra a retinopatia da prematuridade, através da 
comparação da quantidade de leite materno recebida entre os 
pacientes que desenvolveram retinopatia da prematuridade e 
aqueles livres da doença. Tentar determinar a quantidade mínima 
necessária e o momento em que o recém-nascido precisa receber 
o leite materno para que esse efeito seja sig nificativo. Métodos: 
Estudo de coorte observacional in cluindo recém-nascidos com 
peso de nascimento inferior a 1500 gramas e/ou com idade 
gestacional inferior a 32 se manas, nascidos no período de janeiro 
de 2011 a outubro de 2014 e internados nas primeiras 24 horas 
de vida na UTI Neonatal do Hospital da Criança Conceição 
em Porto Alegre. Resultados: A prevalência da retinopatia 
da prematuridade em qualquer grau foi de 31% (100 casos em 
323 pacientes) e a de retinopatia da prematuridade grave foi 
de 9% (29 casos em 323 pacientes). A mediana da quantidade 
de leite materno recebida pelos pacientes foi de 10,2 mL/kg/dia 
entre os pacientes sem retinopatia da prematuridade (amplitude 
interquartil 1,5-25,5) e de 4,9 mL/kg/dia entre os pacientes 
com retinopatia da prematuridade (0,3-15,4). A quantidade de 
leite materno recebida nas primeiras seis semanas de vida foi 
inversamente associada à incidência de retinopatia da prema-
turidade em qualquer grau e de retinopatia da prematuridade 
grave nas análises univariadas, mas a significância estatística não 
se manteve após análise multivariada para controle de fatores 
confundidores na maioria dos períodos avaliados, exceto na 
sexta semana de vida. Conclusão: Pequenas quantidades de leite 
materno não são suficientes para prevenção de retinopatia da 
prematuridade em recém-nascidos com de risco para a doença.
Descritores: Retinopatia da prematuridade; Leite humano; Alei-
tamento materno; Recém-nascido de muito baixo peso; Fator de 
crescimento insulin-like I; Recém-nascido prematuro
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INTRODUCTION
Retinopathy of prematurity (ROP) is a vasoprolifera-
tive eye disease secondary to the incomplete vasculari-
zation of the retina in premature infants(1). The preva-
lence of ROP has increased along with improvements 
in neonatal services in many countries. Because ROP 
can cause blindness(2), it results in social and financial 
burdens to society. Furthermore, irreversibly impaired 
vision also prevents suitable cognitive and psychomotor 
development in affected infants(3).
The etiology of ROP is multifactorial and remains to 
be fully elucidated. Factors involved in its pathogenesis 
include exposure of the developing retina to abnormal 
oxygen levels(4-6) and deficiencies in insulin-like growth 
fator-1 (IGF-1)(7). Human breast milk (BM) contains IGF-1(8) 
and therefore may have a protective effect against the 
development of ROP.
The association between BM intake and ROP has 
been studied with conflicting results. Heller et al.(9) found 
no evidence that BM intake reduces the risk of severe 
ROP (surgically treated) in extremely low-birth-weight 
(ELBW) infants (BW <1000 grams). Hylander et al.(10) 
found that compared with very low-birth-weight (VLBW) 
infants (BW <1500 g) who consumed exclusively infant 
formula, those who consumed BM had a lower incidence 
of ROP. Kao et al.(11) compared the incidence of ROP in 
newborns who received any amount of BM (from their 
mothers or from a milk bank) and those who received 
only infant formula and found no significant association 
between the consumption of BM and ROP risk. Manzoni 
et al.(12) compared 314 newborns fed exclusively BM with 
184 newborns who received only premature infant for-
mula. The incidence of ROP at any stage was significantly 
lower in the newborns who consumed BM.
This variation in study results may be related to the 
amount of BM consumed by premature infants. The 
protective effect of BM may manifest only at higher 
ingestion levels or when BM is consumed at specific 
times, perhaps during the first weeks of life, which is 
when IGF-1 deficiency is involved in the development 
of ROP(7).
The purpose of this study was to assess the protective 
effect of BM against ROP by comparing the amount of 
BM ingested by infants who developed ROP and those 
who did not. The study also aimed to determine the 
minimum amount of BM required and the timing with 




The present study was an observational cohort study 
using retrospective and prospective data. The study po-
pulation comprised newborns with a BW of <1500 g 
or a gestational age of <32 weeks, or both, who were 
hospitalized in the Hospital Criança Conceição (HCC) 
Neonatal Intensive Care Unit (NICU) between January 
2011 and October 2014. Patients were excluded if they 
had major congenital malformations, died before com-
pleting the ophthalmic assessment, or arrived at the 
HCC from other hospitals after 24 h of life.
The retrospective data were collected using patient 
records from the HCC Medical Archive and Statistics 
Service. The prospective portion of the research was con-
ducted by monitoring patients during their stays in the 
NICU and Intermediate Care Unit and, after discharge, 
during follow-up visits to the Ophthalmology Outpatient 
Clinic.
The following variables were evaluated: (1) delivery 
data including prenatal care, use of antenatal corticos-
teroids, presence of ovular infection, presence of pree-
clampsia, and mode of delivery; (2) newborn data, 
in cluding sex, BW, gestational age (established through 
echography when obstetric ultrasound was performed 
up to 12 weeks of gestational age or with a Ballard 
score in the absence of early ultrasound), weight clas-
sification for gestational age (small, appropriate, or 
large), fifth-minute Apgar score, score for neonatal acute 
physiology, perinatal extension II), transfer from another 
hospital, and twinning; (3) newborn NICU evolution data, 
including the use of dopamine, duration of mechanical 
ventilation, duration of nasal continuous positive airway 
pressure use, total duration of oxygen use, number 
of transfusions of red cell concentrates during NICU 
hospitalization, duration of use of parenteral nutrition, 
age at which enteral feeding started, age at which the 
consumption of a full enteral diet was achieved, length 
of hospital stay, and the presence of respiratory distress 
syndrome, early- or late-onset sepsis, fungal sepsis (all 
sepsis diagnoses were confirmed with blood culture), 
hyperglycemia, necrotizing enterocolitis (NEC), broncho-
pulmonary dysplasia (BPD), intraventricular hemorrhage 
grade III or IV, and persistent arterial duct; (4) feeding 
data including the amount of BM received as measu-
red daily in milliliters per kilogram until the newborns 
completed 6 weeks of life or were discharged; (5) and 
ophthalmic assessment data including the development 
and severity of ROP and need for surgical treatment 
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using laser photocoagulation. Disease staging was per-
formed according to the International Classification of 
ROP (International Committee for the Classification 
of ROP, 2005). Retina mapping tests are included in 
the routine care of the HCC Neonatology Service and 
were performed by a single trained ophthalmologist. 
Ophthalmic follow-up was initiated during hospitali-
zation and maintained on an outpatient basis after 
discharge. The follow-up was considered complete 
when patients were monitored for up to 40 weeks of cor-
rected gestational age or had fully vascularized retinas 
or a minimal avascular area.
This study was approved by the Research Ethics 
Committees at Grupo Hospitalar Conceição and Federal 
University of Rio Grande do Sul. The parents of the pa-
tients in the prospective arm of the study gave informed 
written consent for participation.
Statistical analysis
The calculated sample size was 292 patients based 
on an ROP incidence of 28% (local data), the aim to 
detect an ROP reduction of 50% with 80% power, and 
a level of statistical significance of 0.05. These statistical 
criteria were adopted from a study by Hylander et al.(10), 
demonstrating that VLBW newborns fed BM had an in-
cidence of ROP lower than that of VLBW newborns fed 
exclusively infant formula. Initially, the patients were 
divided into two groups: those with ROP (of any degree) 
and those without ROP.
The quantitative variables were presented as means 
and standard deviation (symmetrical distribution) or 
me dians and interquartile range (asymmetric distribu-
tion). The qualitative variables were described as abso-
lute and relative frequencies.
Student’s t-test (symmetrical distribution) or Mann- 
Whitney test (asymmetric distribution) was applied for 
the comparison of quantitative variables. For the evalua-
tion of the association between qualitative variables, the 
chi-square and Fisher exact tests were used.
The analyses were performed by determining the 
amount of BM intake throughout the study period (first 
42 days of life) and weekly (weeks 1-6). These data 
were used to evaluate the timing for BM intake that 
was effective for preventing ROP. A multivariate analy-
sis was conducted using the Poisson regression with 
adjustment for robust variances to determine the pre-
valence ratios adjusted for the key factors involved. 
Some of the factors identified as significant in the uni-
variate analysis were excluded from the multivariate 
analysis owing to multicollinearity.
Subsequently, the patients were divided into new 
groups: patients with severe ROP (grade ≥3) and pa-
tients without ROP or with mild ROP (grade ≤2). All of the 
analyses were repeated in these new groups. A p value 
of <0.05 was considered statistically significant, and the 
analyses were performed using SPSS version 18.0.
RESULTS
During the study period, 466 newborns with a BW of 
<1500 g or gestational age of <32 weeks, or both, were 
admitted to the HCC NICU within their first 24 h of life. 
Of these patients, 12 were excluded because of major 
congenital malformations and 112 died before comple-
ting the ophthalmic evaluation. A total of 342 patients 
were initially enrolled in the study. Nineteen of these 
patients were excluded because they did not complete 
the ophthalmic evaluation (missed outpatient follow-up 
appointments). The final analysis included 323 patients.
The prevalence of ROP of any degree was 31% (100 
cases) and that of severe ROP was 9% (29 cases). During 
the first 42 days of life, the average daily BM intake was 
13.7 mL/kg (19.1% of the total milk intake). The average 
daily intake of infant formula during this period was 
57.9 mL/kg (80.9% of the total amount of enteral nutri-
tion consumed).
In the initial analysis comparing patients with ROP 
of any degree and patients without ROP, the median 
daily BM intakes were 4.9 mL/kg (interquartile range, 
0.3-15.4) and 10.2 mL/kg (1.5-25.5), respectively. In the 
univariate analysis, the presence of ROP had a statisti-
cally significant association with several of the variables 
studied, including BM intake during the first 42 days of 
life and, separately, during all 6 weeks evaluated (Ta-
ble 1). In the multivariate analysis, only fungal sepsis, 
persistent arterial duct, gestational age, and BM intake 
at week 6 remained significantly associated with the 
development of ROP (Table 2).
In the second analysis comparing patients with se-
vere ROP and patients without ROP or with mild ROP, 
the median daily BM intakes were 8.4 mL/kg (1.3-23.1) 
and 2.4 mL/kg (0.12-12.6), respectively. In the univariate 
analysis, the presence of severe ROP had a statistically 
significant association with several variables studied, 
including BM intake during the first 42 days of life and 
separately in weeks 1, 4, 5, and 6 (Table 3). In the multi-
variate analysis, only fungal sepsis, BPD, and mechanical 
ventilation time remained significantly associated with 
the development of severe ROP (Table 4).
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Table 1. Comparison between patients included in the study and those who died before completing the ophthalmic evaluation
Patients included 323 patients Deaths 102 patients P value
Prenatal care 295 (91.3%) 90 (88.5%) <0.496
Antenatal steroids 216 (66.9%) 43 (42.3%) <0.001
Ovular infection 032 (10.0%) 23 (22.9%) <0.023
ROM >18 h 066 (20.4%) 16 (16.2%) <0.416
Preeclampsia 114 (35.3%) 25 (24.8%) <0.060
Male 162 (50.2%) 53 (52.4%) <0.776
Fifth-minute Apgar score <7 053 (16.4%) 57 (56.3%) <0.001
Birth weight 1200.8 ± 264.3 785.1 ± 206.0 <0.001
Gestational age 0030.1 ± 002.3 026.1 ± 002.8 <0.001
SNAPPE II 15 (8-29) 53 (40-70.5) <0.001
Data expressed as means ± standard deviation, median and interquartile range, or in proportion (%) when applicable. 
ROM= rupture of membranes; SNAPPE II= score for neonatal acute physiology, perinatal extension II.
Table 2. Association between the variables studied and ROP in the univariate analysis
Newborns without ROP 223 patients (69%) Newborns with ROP 100 patients (31%) P value
Prenatal 206 (92.4%) 89 (89%) <0.425
Antenatal corticosteroids 152 (68.2%) 64 (64%) <0.544
Ovular infection 025 (11.2%) 17 (17%) <0.253
Preeclampsia 084 (37.7%) 30 (30%) <0.262
Vaginal delivery 074 (33.2%) 37 (37%) <0.581
Male gender 107 (48.0%) 55 (55%) <0.332
Small for gestational age 103 (46.2%) 34 (34%) <0.085
Transfer 017 (07.6%) 8 (8%) <0.923
Twinning 048 (21.5%) 15 (15%) <0.240
Fifth-minute Apgar score <7 023 (10.5%) 29 (29%) <0.001
RDS 099 (44.4%) 86 (86%) <0.001
Early onset sepsis 004 (01.8%) 01 (01%) <0.635
Late-onset sepsis 057 (25.6%) 57 (57%) <0.001
Fungal sepsis 006 (02.7%) 12 (12%) <0.002
Use of dopamine 049 (22.0%) 44 (44%) <0.001
Hyperglycemia 019 (08.5%) 17 (17%) <0.034
NEC 019 (08.5%) 19 (19%) <0.009
BPD 037 (16.6%) 57 (57%) <0.001
IVH III/IV 005 (02.2%) 17 (17%) <0.001
PDA 031 (13.9%) 47 (47%) <0.001
Birth weight 1272 ± 237 1041 ± 253 <0.001
Gestational age 30.8 ± 2 28.6 ± 2.2 <0.001
SNAPPE II 13 (5-23) 25 (13-47.5) <0.001
No. of RCC transfusions 1 (0-2) 5 (2-9) <0.001
MV duration 0 (0-3) 9.5 (1-38.5) <0.001
Nasal CPAP duration 3 (1-8) 8.5 (3-15) <0.001
Supplemental O2 days 5 (1-16) 35 (11-65.5) <0.001
Parenteral nutrition time 3 (2-6) 6 (3.5-10) <0.001
Enteral feeding start 4.7 (2-6) 6 (3.5-10) <0.001
Full enteral feeding 16 (2-24) 28.5 (17-40) <0.001
Length of hospital stay 48 ± 20 80 ± 39 <0.001
BM 42 days 10.2 (1.5-25.5) 4.9 (0.3-15.4) <0.005
BM week 1 0.43 (0-4.3) 0 (0-1.1) <0.003
BM week 2 7 (0-22.6) 1.4 (0-10.5) <0.003
BM week 3 5.9 (0-23) 2.2 (0-16.7) <0.034
BM week 4 7.9 (0-27.6) 1.4 (0-14.5) <0.015
BM week 5 6.9 (0-34.1) 1.3 (0-14.3) <0.003
BM week 6 4 (0-37) 0 (0-15) <0.016
Data expressed as means ± standard deviation, median and interquartile range, or as a rate (%) when applicable.
BM= breast milk; BPD= bronchopulmonary dysplasia; CPAP= continuous positive airway pressure; IVH III/IV= grade III or IV intraventricular hemorrhage; MV= mechanical ventilation; 
NEC= necrotizing enterocolitis; O2= oxygen; PDA= patent ductus arteriosus; RCC= red cell concentrates; RDS= respiratory distress syndrome; ROP= retinopathy of prematurity; 
SNAPPE II= score for neonatal acute physiology, perinatal extension II.
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Table 4. Association between the variables studied and severe ROP in the univariate analysis
Newborns without severe ROP 294 patients (91%) Newborns with severe ROP 29 patients (9%) P value
Prenatal 288 (91.8%) 25 (86.2%) <0.298
Ovular infection 37 (12.6%) 05 (17.2%) <0.560
Antenatal corticosteroids 202 (68.7%) 14 (48.2%) <0.029
Preeclampsia 109 (37.0%) 05 (17.2%) <0.044
Vaginal delivery 097 (33.0%) 14 (48.2%) <0.105
Male gender 146 (49.7%) 16 (55.2%) <0.571
Small for gestational age 127 (43.2%) 10 (34.5%) <0.433
Transfer 022 (07.5%) 03 (10.3%) <0.480
Twinning 059 (20.1%) 04 (13.8%) <0.623
5th-minute Apgar <7 040 (13.8%) 12 (42.9%) <0.001
RDS 157 (53.4%) 28 (96.6%) <0.003
Early-onset sepsis 005 (01.7%) 0 (0%) <1.000
Late-onset sepsis 097 (33.0%) 17 (58.6%) <0.008
Fungal sepsis 011 (03.7%) 07 (24.1%) <0.001
Use of dopamine 076 (25.9%) 17 (58.6%) <0.001
Hyperglycemia 029 (09.9%) 07 (24.1%) <0.019
NEC 028 (09.5%) 10 (34.5%) <0.001
BPD 069 (23.5%) 25 (86.2%) <0.001
IVH III/IV 014 (04.8%) 08 (27.6%) <0.001
PDA 062 (21.1%) 16 (55.2%) <0.001
Birth weight 1230 ± 250 901 ± 211 <0.001
Gestational age 30.4 ± 2.2 27.5.6 ± 2.1 <0.001
SNAPPE II 15 (8-15) 39 (16.5-52.5) <0.001
No. of RCC transfusions 0 1 (0-3.3) 10 (05.5-16.5) <0.001
MV duration 0 (0-7) 49 (15.5-62.5) <0.001
Nasal CPAP duration 03 (1-10) 9 (5-15) <0.028
Supplemental O2 days 7 (2-26.3) 68 (44-91) <0.001
Parenteral nutrition time 16 (10.8-23.6) 35 (20-60) <0.001
Enteral feeding start 4 (2-7) 6 (4-12) <0.006
Full enteral feeding 17 (13-28) 34 (22-53.5) <0.020
Length of hospital stay 53 ± 23.6 106.8 ± 53.2 <0.001
BM 42 days 8.4 (1.3-23.1) 2.4 (0.12-12.6) <0.034
BM week 1 0 (0-3.6) 0 (0-1.3) <0.044
BM week 2 5.6 (0-21.3) 0 (0-7.1) <0.087
BM week 3 4.8 (0-21.2) 1.1 (0-15.7) <0.085
BM week 4 6.6 (0-25) 0 (0-6.6) <0.048
BM week 5 6 (0-28) 0 (0-10.9) <0.030
BM week 6 3.6 (0-30) 0 (0-4.2) <0.042
Data expressed as means ± standard deviation, median and interquartile range, or as a rate (%) when applicable.
BM= breast milk; BPD= bronchopulmonary dysplasia; CPAP= continuous positive airway pressure; IVH III/IV= grade III or IV intraventricular hemorrhage; MV= mechanical ventilation; 
NEC= necrotizing enterocolitis; O2= oxygen; PDA= patent ductus arteriosus; RCC= red cell concentrates; RDS= respiratory distress syndrome; ROP= retinopathy of prematurity; 
SNAPPE II, score for neonatal acute physiology, perinatal extension II.
Table 3. Variables significantly associated with ROP in the multivariate 
analysis
Relative risk 95% CI P value
Fungal sepsis 1.47 1.06-2.03 0.021
PDA 1.58 1.18-2.12 0.002
Gestational age 0.87 0.80-0.95 0.002
BM week 6 0.99 0.98-1.00 0.041
The following variables were also used in the multivariate analysis but did not maintain 
statistical significance: late-onset sepsis; necrotizing enterocolitis; bronchopulmonary 
dysplasia; grade III or IV intraventricular hemorrhage; score for neonatal acute phy-
siology, perinatal extension II; and mechanical ventilation time. 
BM= breast milk; CI= confidence interval; PDA= patent ductus arteriosus; ROP= 
retinopathy of prematurity.
DISCUSSION
In the present study, BM showed a protective effect 
against ROP in the univariate analysis during all periods 
evaluated; however, only BM intake during the sixth 
week of life maintained statistical significance after ad-
justing for confounding variables. The vast majority of 
premature infants at risk for ROP in our study popula-
tion received a mixed diet that contained predominantly 
of infant formula and a very low mean amount of BM: 
only 13.7 mL/kg per day during the first 42 days of life 
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(19.1% of the total milk intake during the period). This 
low BM intake is likely inadequate for the prevention 
of ROP. 
The inadequate protective effect of BM against ROP 
observed in our study may also have been the result 
of BM processing. Most of the BM obtained at HCC is 
pasteurized. Only BM obtained at the bedside at the 
time of feeding is offered fresh (a practice that remains 
infrequent in our unit). All frozen BM used during the 
study period was both thawed and pasteurized, and the 
pasteurization process reduces the amounts of IGF-1 in 
BM. A study by Goelz et al.(13) showed that after 30 min of 
heating, the amount of IGF-1 in BM is reduced by 39.4%.
Furthermore, BM may be more effective in the pre-
vention of ROP when intake occurs at a different time, 
such as after the sixth week of life. BM intake during 
the sixth week of life in our study had a protective 
effect against ROP despite the small amounts of BM 
consumption by the newborns in the cohort.
A 2013 study by Manzoni et al.(12) firmly established 
the protective effect of the exclusive feeding of BM (fresh 
or frozen and thawed) compared with the exclusive 
feeding of infant formula. A newly published study by 
Spiegler et al.(14) also compared VLBW newborns who 
received exclusively BM and those receiving exclusively 
infant formula and showed a greater risk for the develop-
ment of BPD, NEC, and ROP in infants fed formula alone.
The conflicting results of previous studies may be 
due to differences in the amount of BM consumed by 
the newborns in the study populations. For example, 
Heller et al.(9) found no association between BM intake 
and reduced risk of ROP in ELBW infants who underwent 
surgery, but the BM intake in their study population was 
low, accounting for only approximately 15% of the total 
feeding volume during hospitalization. Hylander et al.(10) 
reported that compared with VLBW infants fed exclusi-
vely formula, those who consumed BM had a lower in-
cidence of ROP. Notably, the breastfeeding rate among 
the mothers of these infants was 57%, which is quite 
high compared with the rate of 36% reported nationally 
in the United States.
A recently published meta-analysis by Zhou et al.(15) 
supported the hypothesis that BM consumption redu-
ces the risk of ROP. The authors selected longitudinal 
studies comparing the incidence of ROP in newborns 
fed BM and those fed infant formula. For ROP at any 
stage, the odds ratios with 95% confidence interval 
were as follows: BM alone versus infant formula in any 
amount: 0.29 (0.12-0.72); predominantly BM versus 
predominantly infant formula: 0.51 (0.26-1.03); BM in 
any amount versus infant formula alone: 0.54 (0.15-1.96); 
and BM alone versus infant formula alone: 0.25 (0.13-
0.49). For severe ROP, the results were 0.11 (0.04-
0.30), 0.16 (0.06-0.43), 0.42 (0.08-2.18), and 0.10 
(0.04-0.29), respectively. The authors concluded that 
the limited current evidence available suggests that 
BM intake plays a protective role in the prevention of 
both ROP at any stage and severe ROP in very prema-
ture newborns. The results of this meta-analysis clearly 
demonstrate the association between the amount of 
BM consumed and the level of protection against ROP. 
However, although this association is undeniable when 
BM feeding is exclusive, it is difficult to demonstrate 
when infants are fed a mixture of BM and formula.
Similar conclusions have been drawn regarding the 
importance of BM intake during the later perinatal period. 
Okamoto et al.(16) undertook a study of possible risk 
factors for the progression of ROP to retinal detachment 
in ELBW infants. Their results showed a substantial di-
fference in the daily intake of BM in infants with and 
without retinal detachment when evaluated with res-
pect to gestational age during the period of 5-7 weeks’ 
postnatal age. Although IGF-1 deficiency during the 
first weeks of life is known to be related to ROP(7), other 
components in BM may also influence the development 
of ROP and contribute to a protective effect during la-
ter perinatal periods. Human milk contains long-chain 
polyunsaturated fatty acids and antioxidant enzymes, 
including inositol(17,18). The poor antioxidant defenses of 
premature infants and their reduced ability to synthe-
size long-chain polyunsaturated fatty acids have been 
implicated in the pathogenesis of ROP(19, 20). Moreover, 
inositol is an essential nutrient for the growth and sur-
vival of human cells, and its administration to preterm 
Table 5. Risk factors significantly associated with severe ROP in the 
multivariate analysis
Relative risk 95% CI P value
Fungal sepsis 3.64 1.57-8.41 <0.003
BPD 4.20 1.28-13.82 <0.018
MV duration 1.01 1.01-01.02 <0.001
The following variables were also used in the multivariate analysis but did not maintain 
statistical significance: late-onset sepsis, gestational age and amount of BM received 
in the first 42 days of life. Nnecrotizing enterocolitis; grade III or IV intraventricular 
hemorrhage; score for neonatal acute physiology, perinatal extension II. 
BM= brest milk; BPD= bronchopulmonary dysplasia; CI= confidence interval; MV= 
mechanical ventilation; ROP= retinopathy of prematurity.
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infants results in a lower incidence of ROP(21). The risk 
of developing severe ROP is higher in children with low 
serum inositol concentrations(22). 
A positive aspect of our study was our attempt to 
overcome the methodological problems of previous stu-
dies by using an experimental design specifically aimed 
at identifying the amount of BM needed to prevent ROP 
in newborns at risk for the disease. Also notable is the 
successful follow-up of our cohort, in which only 19 of 
342 patients (5.5%) were lost owing to a failure to com-
plete the ophthalmic assessment at the outpatient clinic. 
Our study is limited by the low BM intake of new-
borns at risk for ROP in our population. This limitation 
highlights the need to strengthen incentives for milking 
by mothers of preterm infants. Regardless of the amount 
of protection BM intake may offer against ROP, the 
feeding of BM in premature infants is known to reduce 
the risk of various negative outcomes of prematurity, in -
cluding late-onset sepsis and NEC. BM intake also redu-
ces the length of NICU hospitalization(23).
Although a randomized clinical trial would be the 
ideal experimental design for investigating the associa-
tion between BM and the development of ROP, it would 
be unethical to give BM to one study group and not to 
another. Therefore, prospective cohort studies are the 
most appropriate option. Cohort studies analyze associa-
tions of exposure and effect by comparing the occurrence 
of diseases between patients exposed and not exposed 
to a risk factor or, as in the present study, a protective 
factor. This type of study may present confounding bia-
ses, which arise because of differences inherent in the 
probabilities of falling ill among exposed and unexposed 
populations. Because ROP has a multifactorial etiology 
that remains to be fully elucidated, its risk and protec-
tive factors are even more difficult to define. Compared 
with newborns who are smaller and more immature, 
newborns with higher BWs and greater gestational age 
have a lower risk of developing ROP yet tend to achieve 
a fuller enteral diet more quickly and, consequently, a 
higher amount of BM. In an attempt to minimize con-
founding factors, we performed a multivariate analysis 
in which the predictor variables were analyzed simulta-
neously and the effect of each variable was adjusted to 
that of the others.
The results of our study allow us to conclude that small 
amounts of BM intake are inadequate to prevent ROP. Fu-
ture studies that investigate a possible cut-off point-that 
is, a minimum amount of BM intake that confers a pro-
tective effect against ROP-must include newborns who 
consume larger amounts of BM. Our study, despite its 
limitations, demonstrated a significant protective effect of 
BM against ROP in an analysis of BM intake during the 
sixth week of life. Therefore, per-period analyses that 
evaluate BM intake and ROP risk, particularly during 
later perinatal periods such as the fifth to eighth weeks 
of life, would be of special interest
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